Headlines about a Russian 'cancer vaccine' that will be 'free for everyone' have been circulating since 2022, and they resurfaced again in 2026 as Russia's Health Ministry moved to add personalised cancer vaccines and related immunotherapies to its compulsory medical insurance system. The vaccine most often named is Enteromix, developed with the Federal Medical-Biological Agency (FMBA) and the Gamaleya Center. So what has actually been proven about Enteromix, and how does it compare to the mRNA cancer vaccine research that has been through proper peer review? Here is what the record actually shows. What Enteromix Is and What's Been Claimed Enteromix is a personalised vaccine platform that combines an mRNA component with oncolytic viral vectors, designed to train the immune system to recognise neoantigens unique to a patient's own tumour. According to statements from FMBA head Veronika Skvortsova and Gamaleya officials, Enteromix completed preclinical testing showing tumour size reductions and slowed growth in animal models, with some assessments reporting reductions of 60-80%. A separate melanoma-focused candidate has been cited with up to 90% efficacy against metastases in animal studies. Officials have said the vaccine 'will soon be available for public use' and would be free to patients as part of state healthcare. What Has Actually Been Published A first-in-human safety trial of Enteromix, involving 48 volunteers, began in June 2025 to assess safety and dosing. As of mid-2026, no peer-reviewed clinical trial results for Enteromix have been published in an indexed medical journal. A Lancet Oncology commentary from late 2025 specifically named the September 2025 FMBA announcement of Enteromix's success as an example of the kind of unverified claim that complicates public understanding of mRNA therapy research, contrasting it with vaccine research advancing through transparent, internationally reviewed trials. The promise of free public availability 'by 2025' made in 2022 has not materialised; the vaccine is now folded into a 2026 plan to integrate such therapies into compulsory insurance once trials confirm safety and efficacy, a condition that has not yet been met in public, reviewable data. How This Compares to Verified mRNA Cancer Vaccine Trials For contrast, the Moderna/Merck personalised mRNA cancer vaccine mRNA-4157 (V940), given alongside pembrolizumab, has been through a randomised, controlled Phase 2b trial (KEYNOTE-942) in patients with resected high-risk melanoma, with results published in peer-reviewed journals including The Lancet. That trial showed a statistically significant reduction in recurrence risk compared with pembrolizumab alone, and the combination has since progressed into Phase 3 testing. This is the standard against which any 'cancer vaccine' claim should be measured: a randomised trial, a defined patient population, a measured outcome, and a result that other scientists can review and attempt to replicate. Enteromix has not yet reached that bar in public, reviewable form. What This Means for Doctors and Patients Indian oncology and primary care patients are exposed to this news through social media, often stripped of nuance ('Russia cures cancer, free for all'). Some patients facing a cancer diagnosis may ask whether they should delay surgery, chemotherapy, or radiotherapy to wait for an mRNA vaccine. The honest answer is that no personalised cancer vaccine, Russian or Western, is currently an approved substitute for standard-of-care treatment. The most advanced candidates are adjuncts being trialled alongside existing therapy, not replacements for it, and none are available outside clinical trials. Delaying proven treatment on the basis of preliminary or unverified claims carries real risk. Q&A: What Patients Are Asking Q: Has Russia cured cancer with a vaccine? A: No. Russia has announced preclinical (animal model) data and started a small first-in-human safety trial for Enteromix in 2025. No published clinical trial has shown it cures cancer in humans. Q: Is Enteromix available for free in Russia right now? A: No. It is in early-phase trials. Russia's 2026 plan is to integrate such vaccines into compulsory insurance once trials confirm safety and efficacy, which has not yet happened in publicly reviewable form. Q: How is mRNA-4157 different from Enteromix? A: mRNA-4157 (Moderna/Merck) has published, peer-reviewed Phase 2b randomised trial data showing benefit alongside pembrolizumab in resected melanoma, and is now in Phase 3. Enteromix has preclinical animal data and an early safety trial, but no published human efficacy data yet. Q: Should a cancer patient delay treatment to wait for these vaccines? A: No. None of these vaccines are approved replacements for surgery, chemotherapy, radiotherapy or existing immunotherapy. Delaying standard treatment based on unverified or preliminary announcements can allow disease to progress. How Doctrust Connects Viral health claims like 'free cancer cure announced' put doctors in a difficult position: patients arrive with hope and headlines, and the doctor has to deliver context without sounding dismissive. Doctrust helps clinics handle this well by giving doctors a quick, structured way to record what a patient has read or asked about, attach a short evidence-based note for the file, and set a follow-up reminder to revisit the conversation at the next visit. Over time this builds a record of patient health literacy and concerns that helps you communicate more effectively and reduces the risk of a patient quietly delaying treatment based on something they saw online. Book a free demo at www.doctrust.in to see how Doctrust supports better-informed conversations with your patients.